86 results on '"IGOILLO ESTEVE, M"'
Search Results
2. Palmitate induces a pro-inflammatory response in human pancreatic islets that mimics CCL2 expression by beta cells in type 2 diabetes
- Author
-
Igoillo-Esteve, M., Marselli, L., Cunha, D. A., Ladrière, L., Ortis, F., Grieco, F. A., Dotta, F., Weir, G. C., Marchetti, P., Eizirik, D. L., and Cnop, M.
- Published
- 2010
- Full Text
- View/download PDF
3. The long lifespan and low turnover of human islet beta cells estimated by mathematical modelling of lipofuscin accumulation
- Author
-
Cnop, M., Hughes, S. J., Igoillo-Esteve, M., Hoppa, M. B., Sayyed, F., van de Laar, L., Gunter, J. H., de Koning, E. J. P., Walls, G. V., Gray, D. W. G., Johnson, P. R. V., Hansen, B. C., Morris, J. F., Pipeleers-Marichal, M., Cnop, I., and Clark, A.
- Published
- 2010
- Full Text
- View/download PDF
4. Longevity of human islet α- and β-cells
- Author
-
Cnop, M., Igoillo-Esteve, M., Hughes, S. J., Walker, J. N., Cnop, I., and Clark, A.
- Published
- 2011
- Full Text
- View/download PDF
5. Causes and cures for endoplasmic reticulum stress in lipotoxic β-cell dysfunction
- Author
-
Cnop, M., Ladrière, L., Igoillo-Esteve, M., Moura, R. F., and Cunha, D. A.
- Published
- 2010
- Full Text
- View/download PDF
6. Mutations in YIPF5 are a novel cause of neonatal diabetes, highlighting the critical role of endoplasmic reticulum-to-Golgi trafficking in human beta cell survival
- Author
-
De Franco, E, Lytrivi, M, Patel, K, Igoillo-Esteve, M, Wakeling, M, Haliloglu, B, Hattersley, AT, De Franco, E, Lytrivi, M, Patel, K, Igoillo-Esteve, M, Wakeling, M, Haliloglu, B, Hattersley, AT, and Yeditepe Üniversitesi
- Abstract
… European Assoc Study Diabetes Wellcome Trust Senior Investigator Grant Supported by: Wellcome Trust Senior Investigator Grant to SE and ATH
- Published
- 2018
7. Erratum to: Palmitate induces a pro-inflammatory response in human pancreatic islets that mimics CCL2 expression by beta cells in type 2 diabetes
- Author
-
Igoillo-Esteve, M., Marselli, L., Cunha, D. A., Ladrière, L., Ortis, F., Grieco, F. A., Dotta, F., Weir, G. C., Marchetti, P., Eizirik, D. L., and Cnop, M.
- Published
- 2012
- Full Text
- View/download PDF
8. DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients
- Author
-
Volkmar, M, Dedeurwaerder, S, Cunha, Da, Ndlovu, Mn, Defrance, M, Deplus, R, Calonne, E, Volkmar, U, Igoillo Esteve, M, Naamane, N, DEL GUERRA, Silvia, Masini, Matilde, Bugliani, Marco, Marchetti, Piero, Cnop, M, Eizirik, Dl, and Fuks, F.
- Subjects
endocrine system ,DNA methylation ,pancreatic islets ,Transcription, Genetic ,endocrine system diseases ,DNA Fingerprinting ,Article ,Sciences biomédicales ,Cell Line ,Epigenesis, Genetic ,Rats ,Islets of Langerhans ,Glucose ,Diabetes Mellitus, Type 2 ,Genetic Loci ,Animals ,Humans ,CpG Islands ,type 2 diabetes ,Promoter Regions, Genetic ,Biologie ,Aged - Abstract
In addition to genetic predisposition, environmental and lifestyle factors contribute to the pathogenesis of type 2 diabetes (T2D). Epigenetic changes may provide the link for translating environmental exposures into pathological mechanisms. In this study, we performed the first comprehensive DNA methylation profiling in pancreatic islets from T2D and non-diabetic donors. We uncovered 276 CpG loci affiliated to promoters of 254 genes displaying significant differential DNA methylation in diabetic islets. These methylation changes were not present in blood cells from T2D individuals nor were they experimentally induced in non-diabetic islets by exposure to high glucose. For a subgroup of the differentially methylated genes, concordant transcriptional changes were present. Functional annotation of the aberrantly methylated genes and RNAi experiments highlighted pathways implicated in β-cell survival and function; some are implicated in cellular dysfunction while others facilitate adaptation to stressors. Together, our findings offer new insights into the intricate mechanisms of T2D pathogenesis, underscore the important involvement of epigenetic dysregulation in diabetic islets and may advance our understanding of T2D aetiology. © 2012 European Molecular Biology Organization., SCOPUS: ar.j, FLWOA, info:eu-repo/semantics/published
- Published
- 2012
- Full Text
- View/download PDF
9. CO-51: La déficience de TRMT10A, une méthyltransférase d'ARNt, active la voie intrinsèque de l'apoptose dans les cellules bêta-pancréatiques
- Author
-
Igoillo-Esteve, M., primary, Cosentino, C., additional, Oltean, T., additional, Atta, M., additional, Ravanat, J., additional, Eizirik, D., additional, and Cnop, M., additional
- Published
- 2016
- Full Text
- View/download PDF
10. CAD-17: Le transcriptome rencontre le protéome : un aperçu des médiateurs de lipotoxicité dans les cellules β-pancréatiques
- Author
-
Ghaddar, K., primary, Lytrivi, M., additional, Lopes, M., additional, Igoillo-Esteve, M., additional, Cunha, D.A., additional, Marchetti, P., additional, Eizirik, D.L., additional, Ortsäter, H., additional, and Cnop, M., additional
- Published
- 2016
- Full Text
- View/download PDF
11. The long lifespan and how turnover of human islet beta cells estimated by mathematical modelling of lipofuscin accumulation
- Author
-
Cnop, M, Hughes, S.j., Igoillo-Esteve, M, Hoppa, M.b., Sayyed, F, Van De Laar, L, Gunter, J.h., De Koning, E.j.p., Walls, G.v., Gray, D.w.g., Johnson, P.r.v., Hansen, B.c., Morris, J.f., Marichal, Miriam, Cnop, Ivan, Analysis, Mathematics in Education, and Pathological Anatomy
- Subjects
Age Distribution ,Cse of Death ,Lipofuscin - Abstract
AIMS/HYPOTHESIS: Defects in pancreatic beta cell turnover are implicated in the pathogenesis of type 2 diabetes by genetic markers for diabetes. Decreased beta cell neogenesis could contribute to diabetes. The longevity and turnover of human beta cells is unknown; in rodents estimated. Intracellular lipofuscin body (LB) accumulation is a hallmark of ageing in neurons. To estimate the lifespan of human beta cells, we measured beta cell LB accumulation in individuals aged 1-81 years. METHODS: LB content was determined by electron microscopical morphometry in sections of beta cells from human (non-diabetic, n = 45; type 2 diabetic, n = 10) and non-human primates (n = 10; 5-30 years) and from 15 mice aged 10-99 weeks. Total cellular LB content was estimated by three-dimensional (3D) mathematical modelling. RESULTS: LB area proportion was significantly correlated with age in human and non-human primates. The proportion of human LB-positive beta cells was significantly related to age, with no apparent differences in type 2 diabetes or obesity. LB content was low in human insulinomas (n = 5) and alpha cells and in mouse beta cells (LB content in mouse the LB-positive human beta cells (representing aged cells) increased from >or=90% (or=97% (>20 years) and remained constant thereafter. CONCLUSIONS/INTERPRETATION: Human beta cells, unlike those of young rodents, are long-lived. LB proportions in type 2 diabetes and obesity suggest that little adaptive change occurs in the adult human beta cell population, which is largely established by age 20 years.
- Published
- 2010
12. GLP-1 agonists protect pancreatic {beta}-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB
- Author
-
Cunha, Da, Ladrière, L, Ortis, F, IGOILLO ESTEVE, M, Gurzov, En, Lupi, R, Marchetti, Piero, Eizirik, Dl, and Cnop, M.
- Published
- 2009
13. Glucagon-Like Peptide-1 Agonists Protect Pancreatic beta-Cells From Upotoxic Endoplasmic Reticulum Stress Through Upregulation of BiP and JunB
- Author
-
Cunha, DA, Ladriere, L, Ortis, F, Igoillo-Esteve, M, Gurzov, EN, Lupi, R, Marchetti, P, Eizirik, DL, Cnop, M, Cunha, DA, Ladriere, L, Ortis, F, Igoillo-Esteve, M, Gurzov, EN, Lupi, R, Marchetti, P, Eizirik, DL, and Cnop, M
- Abstract
OBJECTIVE: Chronic exposure of pancreatic beta-cells to saturated free fatty acids (FFAs) causes endoplasmic reticulum (ER) stress and apoptosis and may contribute to beta-cell loss in type 2 diabetes. Here, we evaluated the molecular mechanisms involved in the protection of beta-cells from lipotoxic ER stress by glucagon-like peptide (GLP)-1 agonists utilized in the treatment of type 2 diabetes. RESEARCH DESIGN AND METHODS: INS-1E or fluorescence-activated cell sorter-purified primary rat beta-cells were exposed to oleate or palmitate with or without the GLP-1 agonist exendin-4 or forskolin. Cyclopiazonic acid was used as a synthetic ER stressor, while the activating transcription factor 4-C/EBP homologous protein branch was selectively activated with salubrinal. The ER stress signaling pathways modulated by GLP-1 agonists were studied by real-time PCR and Western blot. Knockdown by RNA interference was used to identify mediators of the antiapoptotic GLP-1 effects in the ER stress response and downstream mitochondrial cell death mechanisms. RESULTS: Exendin-4 and forskolin protected beta-cells against FFAs via the induction of the ER chaperone BiP and the antiapoptotic protein JunB that mediate beta-cell survival under lipotoxic conditions. On the other hand, exendin-4 and forskolin protected against synthetic ER stressors by inactivating caspase 12 and upregulating Bcl-2 and X-chromosome-linked inhibitor of apoptosis protein that inhibit mitochondrial apoptosis. CONCLUSIONS: These observations suggest that GLP-1 agonists increase in a context-dependent way the beta-cell defense mechanisms against different pathways involved in ER stress-induced apoptosis. The identification of the pathways modulated by GLP-1 agonists allows for targeted approaches to alleviate beta-cell ER stress in diabetes.
- Published
- 2009
14. Erratum to: Palmitate induces a pro-inflammatory response in human pancreatic islets that mimics CCL2 expression by beta cells in type 2 diabetes
- Author
-
Igoillo-Esteve, M., primary, Marselli, L., additional, Cunha, D. A., additional, Ladrière, L., additional, Ortis, F., additional, Grieco, F. A., additional, Dotta, F., additional, Weir, G. C., additional, Marchetti, P., additional, Eizirik, D. L., additional, and Cnop, M., additional
- Published
- 2011
- Full Text
- View/download PDF
15. Pancreatic β-cells activate a JunB/ATF3-dependent survival pathway during inflammation
- Author
-
Gurzov, E N, primary, Barthson, J, additional, Marhfour, I, additional, Ortis, F, additional, Naamane, N, additional, Igoillo-Esteve, M, additional, Gysemans, C, additional, Mathieu, C, additional, Kitajima, S, additional, Marchetti, P, additional, Ørntoft, T F, additional, Bakiri, L, additional, Wagner, E F, additional, and Eizirik, D L, additional
- Published
- 2011
- Full Text
- View/download PDF
16. The long lifespan and low turnover of human islet beta cells estimated by mathematical modelling of lipofuscin accumulation
- Author
-
Cnop, M., primary, Hughes, S. J., additional, Igoillo-Esteve, M., additional, Hoppa, M. B., additional, Sayyed, F., additional, van de Laar, L., additional, Gunter, J. H., additional, de Koning, E. J. P., additional, Walls, G. V., additional, Gray, D. W. G., additional, Johnson, P. R. V., additional, Hansen, B. C., additional, Morris, J. F., additional, Pipeleers-Marichal, M., additional, Cnop, I., additional, and Clark, A., additional
- Published
- 2009
- Full Text
- View/download PDF
17. Central role and mechanisms of β-cell dysfunction and death in friedreich ataxia-associated diabetes.
- Author
-
Cnop M, Igoillo-Esteve M, Rai M, Begu A, Serroukh Y, Depondt C, Musuaya AE, Marhfour I, Ladrière L, Moles Lopez X, Lefkaditis D, Moore F, Brion JP, Cooper JM, Schapira AH, Clark A, Koeppen AH, Marchetti P, Pandolfo M, and Eizirik DL
- Abstract
Objective: Friedreich ataxia (FRDA) is an autosomal recessive neurodegenerative disease caused in almost all cases by homozygosity for a GAA trinucleotide repeat expansion in the frataxin gene. Frataxin is a mitochondrial protein involved in iron homeostasis. FRDA patients have a high prevalence of diabetes, the pathogenesis of which is not known. We aimed to evaluate the relative contribution of insulin resistance and β-cell failure and the pathogenic mechanisms involved in FRDA diabetes.Methods: Forty-one FRDA patients, 26 heterozygous carriers of a GAA expansion, and 53 controls underwent oral and intravenous glucose tolerance tests. β-Cell proportion was quantified in postmortem pancreas sections from 9 unrelated FRDA patients. Using an in vitro disease model, we studied how frataxin deficiency affects β-cell function and survival.Results: FRDA patients had increased abdominal fat and were insulin resistant. This was not compensated for by increased insulin secretion, resulting in a markedly reduced disposition index, indicative of pancreatic β-cell failure. Loss of glucose tolerance was driven by β-cell dysfunction, which correlated with abdominal fatness. In postmortem pancreas sections, pancreatic islets of FRDA patients had a lower β-cell content. RNA interference-mediated frataxin knockdown impaired glucose-stimulated insulin secretion and induced apoptosis in rat β cells and human islets. Frataxin deficiency sensitized β cells to oleate-induced and endoplasmic reticulum stress-induced apoptosis, which could be prevented by the incretins glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.Interpretation: Pancreatic β-cell dysfunction is central to diabetes development in FRDA as a result of mitochondrial dysfunction and higher sensitivity to metabolic and endoplasmic reticulum stress-induced β-cell death. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
18. Death protein 5 and p53-upregulated modulator of apoptosis mediate the endoplasmic reticulum stress-mitochondrial dialog triggering lipotoxic rodent and human β-cell apoptosis.
- Author
-
Cunha DA, Igoillo-Esteve M, Gurzov EN, Germano CM, Naamane N, Marhfour I, Fukaya M, Vanderwinden JM, Gysemans C, Mathieu C, Marselli L, Marchetti P, Harding HP, Ron D, Eizirik DL, Cnop M, Cunha, Daniel A, Igoillo-Esteve, Mariana, Gurzov, Esteban N, and Germano, Carla M
- Abstract
Environmental factors such as diets rich in saturated fats contribute to dysfunction and death of pancreatic β-cells in diabetes. Endoplasmic reticulum (ER) stress is elicited in β-cells by saturated fatty acids. Here we show that palmitate-induced β-cell apoptosis is mediated by the intrinsic mitochondrial pathway. By microarray analysis, we identified a palmitate-triggered ER stress gene expression signature and the induction of the BH3-only proteins death protein 5 (DP5) and p53-upregulated modulator of apoptosis (PUMA). Knockdown of either protein reduced cytochrome c release, caspase-3 activation, and apoptosis in rat and human β-cells. DP5 induction depends on inositol-requiring enzyme 1 (IRE1)-dependent c-Jun NH₂-terminal kinase and PKR-like ER kinase (PERK)-induced activating transcription factor (ATF3) binding to its promoter. PUMA expression is also PERK/ATF3-dependent, through tribbles 3 (TRB3)-regulated AKT inhibition and FoxO3a activation. DP5(-/-) mice are protected from high fat diet-induced loss of glucose tolerance and have twofold greater pancreatic β-cell mass. This study elucidates the crosstalk between lipotoxic ER stress and the mitochondrial pathway of apoptosis that causes β-cell death in diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
19. Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB.
- Author
-
Cunha DA, Ladrière L, Ortis F, Igoillo-Esteve M, Gurzov EN, Lupi R, Marchetti P, Eizirik DL, Cnop M, Cunha, Daniel A, Ladrière, Laurence, Ortis, Fernanda, Igoillo-Esteve, Mariana, Gurzov, Esteban N, Lupi, Roberto, Marchetti, Piero, Eizirik, Décio L, and Cnop, Miriam
- Abstract
Objective: Chronic exposure of pancreatic beta-cells to saturated free fatty acids (FFAs) causes endoplasmic reticulum (ER) stress and apoptosis and may contribute to beta-cell loss in type 2 diabetes. Here, we evaluated the molecular mechanisms involved in the protection of beta-cells from lipotoxic ER stress by glucagon-like peptide (GLP)-1 agonists utilized in the treatment of type 2 diabetes.Research Design and Methods: INS-1E or fluorescence-activated cell sorter-purified primary rat beta-cells were exposed to oleate or palmitate with or without the GLP-1 agonist exendin-4 or forskolin. Cyclopiazonic acid was used as a synthetic ER stressor, while the activating transcription factor 4-C/EBP homologous protein branch was selectively activated with salubrinal. The ER stress signaling pathways modulated by GLP-1 agonists were studied by real-time PCR and Western blot. Knockdown by RNA interference was used to identify mediators of the antiapoptotic GLP-1 effects in the ER stress response and downstream mitochondrial cell death mechanisms.Results: Exendin-4 and forskolin protected beta-cells against FFAs via the induction of the ER chaperone BiP and the antiapoptotic protein JunB that mediate beta-cell survival under lipotoxic conditions. On the other hand, exendin-4 and forskolin protected against synthetic ER stressors by inactivating caspase 12 and upregulating Bcl-2 and X-chromosome-linked inhibitor of apoptosis protein that inhibit mitochondrial apoptosis.Conclusions: These observations suggest that GLP-1 agonists increase in a context-dependent way the beta-cell defense mechanisms against different pathways involved in ER stress-induced apoptosis. The identification of the pathways modulated by GLP-1 agonists allows for targeted approaches to alleviate beta-cell ER stress in diabetes. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
20. CReP loss-of-function causes beta cell failure and diabetes
- Author
-
Abdulkarim, B., Nicolino, M., Igoillo-Esteve, M., Daures, M., Romero, S., Philippi, A., Senee, V., Lopes, M., Cunha, D. A., Harding, H. P., Bendelac, N., Hattersley, A. T., Ron, D., Cnop, M., and Cécile JULIER
21. Loss-of-function mutations in DNAJC3 cause young-onset diabetes due to oxidative stress and mitochondrial beta cell apoptosis
- Author
-
Abdulkarim, B., Senee, V., Philippi, A., Singh, P., Daures, M., Igoillo-Esteve, M., Chaussenot, A., Nicolino, M., Eizirik, D. L., Cécile JULIER, and Cnop, M.
22. LncRNA ARGI Contributes to Virus-Induced Pancreatic β Cell Inflammation Through Transcriptional Activation of IFN-Stimulated Genes.
- Author
-
González-Moro I, Garcia-Etxebarria K, Mendoza LM, Fernández-Jiménez N, Mentxaka J, Olazagoitia-Garmendia A, Arroyo MN, Sawatani T, Moreno-Castro C, Vinci C, Op de Beek A, Cnop M, Igoillo-Esteve M, and Santin I
- Subjects
- Humans, Transcriptional Activation genetics, Inflammation metabolism, Insulin-Secreting Cells, Diabetes Mellitus, Type 1, RNA, Long Noncoding genetics, RNA, Long Noncoding metabolism
- Abstract
Type 1 diabetes (T1D) is a complex autoimmune disease that develops in genetically susceptible individuals. Most T1D-associated single nucleotide polymorphisms (SNPs) are located in non-coding regions of the human genome. Interestingly, SNPs in long non-coding RNAs (lncRNAs) may result in the disruption of their secondary structure, affecting their function, and in turn, the expression of potentially pathogenic pathways. In the present work, the function of a virus-induced T1D-associated lncRNA named ARGI (Antiviral Response Gene Inducer) is characterized. Upon a viral insult, ARGI is upregulated in the nuclei of pancreatic β cells and binds to CTCF to interact with the promoter and enhancer regions of IFNβ and interferon-stimulated genes, promoting their transcriptional activation in an allele-specific manner. The presence of the T1D risk allele in ARGI induces a change in its secondary structure. Interestingly, the T1D risk genotype induces hyperactivation of type I IFN response in pancreatic β cells, an expression signature that is present in the pancreas of T1D patients. These data shed light on the molecular mechanisms by which T1D-related SNPs in lncRNAs influence pathogenesis at the pancreatic β cell level and opens the door for the development of therapeutic strategies based on lncRNA modulation to delay or avoid pancreatic β cell inflammation in T1D., (© 2023 The Authors. Advanced Science published by Wiley-VCH GmbH.)
- Published
- 2023
- Full Text
- View/download PDF
23. GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models.
- Author
-
Gorgogietas V, Rajaei B, Heeyoung C, Santacreu BJ, Marín-Cañas S, Salpea P, Sawatani T, Musuaya A, Arroyo MN, Moreno-Castro C, Benabdallah K, Demarez C, Toivonen S, Cosentino C, Pachera N, Lytrivi M, Cai Y, Carnel L, Brown C, Urano F, Marchetti P, Gilon P, Eizirik DL, Cnop M, and Igoillo-Esteve M
- Subjects
- Humans, Animals, Mice, Exenatide therapeutic use, Mice, Knockout, Wolfram Syndrome drug therapy, Wolfram Syndrome genetics, Induced Pluripotent Stem Cells, Optic Atrophy pathology, Insulin-Secreting Cells pathology
- Abstract
Aims/hypothesis: Wolfram syndrome is a rare autosomal recessive disorder caused by pathogenic variants in the WFS1 gene. It is characterised by insulin-dependent diabetes mellitus, optic nerve atrophy, diabetes insipidus, hearing loss and neurodegeneration. Considering the unmet treatment need for this orphan disease, this study aimed to evaluate the therapeutic potential of glucagon-like peptide 1 receptor (GLP-1R) agonists under wolframin (WFS1) deficiency with a particular focus on human beta cells and neurons., Methods: The effect of the GLP-1R agonists dulaglutide and exenatide was examined in Wfs1 knockout mice and in an array of human preclinical models of Wolfram syndrome, including WFS1-deficient human beta cells, human induced pluripotent stem cell (iPSC)-derived beta-like cells and neurons from control individuals and individuals affected by Wolfram syndrome, and humanised mice., Results: Our study shows that the long-lasting GLP-1R agonist dulaglutide reverses impaired glucose tolerance in WFS1-deficient mice, and that exenatide and dulaglutide improve beta cell function and prevent apoptosis in different human WFS1-deficient models including iPSC-derived beta cells from people with Wolfram syndrome. Exenatide improved mitochondrial function, reduced oxidative stress and prevented apoptosis in Wolfram syndrome iPSC-derived neural precursors and cerebellar neurons., Conclusions/interpretation: Our study provides novel evidence for the beneficial effect of GLP-1R agonists on WFS1-deficient human pancreatic beta cells and neurons, suggesting that these drugs may be considered as a treatment for individuals with Wolfram syndrome., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
24. In depth functional characterization of human induced pluripotent stem cell-derived beta cells in vitro and in vivo .
- Author
-
Fantuzzi F, Toivonen S, Schiavo AA, Chae H, Tariq M, Sawatani T, Pachera N, Cai Y, Vinci C, Virgilio E, Ladriere L, Suleiman M, Marchetti P, Jonas JC, Gilon P, Eizirik DL, Igoillo-Esteve M, and Cnop M
- Abstract
In vitro differentiation of human induced pluripotent stem cells (iPSCs) into beta cells represents an important cell source for diabetes research. Here, we fully characterized iPSC-derived beta cell function in vitro and in vivo in humanized mice. Using a 7-stage protocol, human iPSCs were differentiated into islet-like aggregates with a yield of insulin-positive beta cells comparable to that of human islets. The last three stages of differentiation were conducted with two different 3D culture systems, rotating suspension or static microwells. In the latter, homogeneously small-sized islet-like aggregates were obtained, while in rotating suspension size was heterogeneous and aggregates often clumped. In vitro function was assessed by glucose-stimulated insulin secretion, NAD(P)H and calcium fluctuations. Stage 7 aggregates slightly increased insulin release in response to glucose in vitro . Aggregates were transplanted under the kidney capsule of NOD-SCID mice to allow for further in vivo beta cell maturation. In transplanted mice, grafts showed glucose-responsiveness and maintained normoglycemia after streptozotocin injection. In situ kidney perfusion assays showed modulation of human insulin secretion in response to different secretagogues. In conclusion, iPSCs differentiated with equal efficiency into beta cells in microwells compared to rotating suspension, but the former had a higher experimental success rate. In vitro differentiation generated aggregates lacking fully mature beta cell function. In vivo , beta cells acquired the functional characteristics typical of human islets. With this technology an unlimited supply of islet-like organoids can be generated from human iPSCs that will be instrumental to study beta cell biology and dysfunction in diabetes., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Fantuzzi, Toivonen, Schiavo, Chae, Tariq, Sawatani, Pachera, Cai, Vinci, Virgilio, Ladriere, Suleiman, Marchetti, Jonas, Gilon, Eizirik, Igoillo-Esteve and Cnop.)
- Published
- 2022
- Full Text
- View/download PDF
25. Current Drug Repurposing Strategies for Rare Neurodegenerative Disorders.
- Author
-
Shah S, Dooms MM, Amaral-Garcia S, and Igoillo-Esteve M
- Abstract
Rare diseases are life-threatening or chronically debilitating low-prevalent disorders caused by pathogenic mutations or particular environmental insults. Due to their high complexity and low frequency, important gaps still exist in their prevention, diagnosis, and treatment. Since new drug discovery is a very costly and time-consuming process, leading pharmaceutical companies show relatively low interest in orphan drug research and development due to the high cost of investments compared to the low market return of the product. Drug repurposing-based approaches appear then as cost- and time-saving strategies for the development of therapeutic opportunities for rare diseases. In this article, we discuss the scientific, regulatory, and economic aspects of the development of repurposed drugs for the treatment of rare neurodegenerative disorders with a particular focus on Huntington's disease, Friedreich's ataxia, Wolfram syndrome, and amyotrophic lateral sclerosis. The role of academia, pharmaceutical companies, patient associations, and foundations in the identification of candidate compounds and their preclinical and clinical evaluation will also be discussed., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Shah, Dooms, Amaral-Garcia and Igoillo-Esteve.)
- Published
- 2021
- Full Text
- View/download PDF
26. A functional genomic approach to identify reference genes for human pancreatic beta cell real-time quantitative RT-PCR analysis.
- Author
-
Alvelos MI, Szymczak F, Castela Â, Marín-Cañas S, de Souza BM, Gkantounas I, Colli M, Fantuzzi F, Cosentino C, Igoillo-Esteve M, Marselli L, Marchetti P, Cnop M, and Eizirik DL
- Subjects
- Humans, Real-Time Polymerase Chain Reaction, Reverse Transcriptase Polymerase Chain Reaction, Genomics methods, Insulin-Secreting Cells metabolism
- Abstract
Exposure of human pancreatic beta cells to pro-inflammatory cytokines or metabolic stressors is used to model events related to type 1 and type 2 diabetes, respectively. Quantitative real-time PCR is commonly used to quantify changes in gene expression. The selection of the most adequate reference gene(s) for gene expression normalization is an important pre-requisite to obtain accurate and reliable results. There are no universally applicable reference genes, and the human beta cell expression of commonly used reference genes can be altered by different stressors. Here we aimed to identify the most stably expressed genes in human beta cells to normalize quantitative real-time PCR gene expression.We used comprehensive RNA-sequencing data from the human pancreatic beta cell line EndoC-βH1, human islets exposed to cytokines or the free fatty acid palmitate in order to identify the most stably expressed genes. Genes were filtered based on their level of significance (adjusted P -value >0.05), fold-change (|fold-change| <1.5) and a coefficient of variation <10%. Candidate reference genes were validated by quantitative real-time PCR in independent samples.We identified a total of 264 genes stably expressed in EndoC-βH1 cells and human islets following cytokines - or palmitate-induced stress, displaying a low coefficient of variation. Validation by quantitative real-time PCR of the top five genes ARF1, CWC15, RAB7A, SIAH1 and VAPA corroborated their expression stability under most of the tested conditions. Further validation in independent samples indicated that the geometric mean of ACTB and VAPA expression can be used as a reliable normalizing factor in human beta cells.
- Published
- 2021
- Full Text
- View/download PDF
27. DNAJC3 deficiency induces β-cell mitochondrial apoptosis and causes syndromic young-onset diabetes.
- Author
-
Lytrivi M, Senée V, Salpea P, Fantuzzi F, Philippi A, Abdulkarim B, Sawatani T, Marín-Cañas S, Pachera N, Degavre A, Singh P, Derbois C, Lechner D, Ladrière L, Igoillo-Esteve M, Cosentino C, Marselli L, Deleuze JF, Marchetti P, Eizirik DL, Nicolino M, Chaussenot A, Julier C, and Cnop M
- Subjects
- Adolescent, Adult, Age Factors, Animals, Cells, Cultured, Diabetes Mellitus, Type 1 metabolism, Female, Humans, Insulin-Secreting Cells metabolism, Loss of Function Mutation, Male, Mice, Mitochondria pathology, Pedigree, Rats, Syndrome, Apoptosis genetics, Diabetes Mellitus, Type 1 genetics, HSP40 Heat-Shock Proteins genetics, Insulin-Secreting Cells physiology, Mitochondria metabolism
- Abstract
Objective: DNAJC3, also known as P58IPK, is an Hsp40 family member that interacts with and inhibits PKR-like ER-localized eIF2α kinase (PERK). Dnajc3 deficiency in mice causes pancreatic β-cell loss and diabetes. Loss-of-function mutations in DNAJC3 cause early-onset diabetes and multisystemic neurodegeneration. The aim of our study was to investigate the genetic cause of early-onset syndromic diabetes in two unrelated patients, and elucidate the mechanisms of β-cell failure in this syndrome., Methods: Whole exome sequencing was performed and identified variants were confirmed by Sanger sequencing. DNAJC3 was silenced by RNAi in INS-1E cells, primary rat β-cells, human islets, and induced pluripotent stem cell-derived β-cells. β-cell function and apoptosis were assessed, and potential mediators of apoptosis examined., Results: The two patients presented with juvenile-onset diabetes, short stature, hypothyroidism, neurodegeneration, facial dysmorphism, hypoacusis, microcephaly and skeletal bone deformities. They were heterozygous compound and homozygous for novel loss-of-function mutations in DNAJC3. DNAJC3 silencing did not impair insulin content or secretion. Instead, the knockdown induced rat and human β-cell apoptosis and further sensitized cells to endoplasmic reticulum stress, triggering mitochondrial apoptosis via the pro-apoptototic Bcl-2 proteins BIM and PUMA., Conclusions: This report confirms previously described features and expands the clinical spectrum of syndromic DNAJC3 diabetes, one of the five monogenic forms of diabetes pertaining to the PERK pathway of the endoplasmic reticulum stress response. DNAJC3 deficiency may lead to β-cell loss through BIM- and PUMA-dependent activation of the mitochondrial pathway of apoptosis.
- Published
- 2021
- Full Text
- View/download PDF
28. tRNA Biology in the Pathogenesis of Diabetes: Role of Genetic and Environmental Factors.
- Author
-
Arroyo MN, Green JA, Cnop M, and Igoillo-Esteve M
- Subjects
- Animals, Diabetes Mellitus, Type 2 metabolism, Gene-Environment Interaction, Humans, Insulin-Secreting Cells metabolism, RNA Processing, Post-Transcriptional genetics, RNA, Transfer metabolism, Diabetes Mellitus, Type 2 genetics, Genetic Predisposition to Disease genetics, Protein Biosynthesis genetics, RNA, Transfer genetics, Transfer RNA Aminoacylation genetics
- Abstract
The global rise in type 2 diabetes results from a combination of genetic predisposition with environmental assaults that negatively affect insulin action in peripheral tissues and impair pancreatic β-cell function and survival. Nongenetic heritability of metabolic traits may be an important contributor to the diabetes epidemic. Transfer RNAs (tRNAs) are noncoding RNA molecules that play a crucial role in protein synthesis. tRNAs also have noncanonical functions through which they control a variety of biological processes. Genetic and environmental effects on tRNAs have emerged as novel contributors to the pathogenesis of diabetes. Indeed, altered tRNA aminoacylation, modification, and fragmentation are associated with β-cell failure, obesity, and insulin resistance. Moreover, diet-induced tRNA fragments have been linked with intergenerational inheritance of metabolic traits. Here, we provide a comprehensive review of how perturbations in tRNA biology play a role in the pathogenesis of monogenic and type 2 diabetes.
- Published
- 2021
- Full Text
- View/download PDF
29. Molecular mechanisms of β-cell dysfunction and death in monogenic forms of diabetes.
- Author
-
Sanchez Caballero L, Gorgogietas V, Arroyo MN, and Igoillo-Esteve M
- Subjects
- Animals, Cell Death, Genetic Predisposition to Disease, Humans, Insulin-Secreting Cells metabolism, Mutation genetics, Transcription Factors metabolism, Diabetes Mellitus genetics, Diabetes Mellitus pathology, Insulin-Secreting Cells pathology
- Abstract
Monogenetic forms of diabetes represent 1%-5% of all diabetes cases and are caused by mutations in a single gene. These mutations, that affect genes involved in pancreatic β-cell development, function and survival, or insulin regulation, may be dominant or recessive, inherited or de novo. Most patients with monogenic diabetes are very commonly misdiagnosed as having type 1 or type 2 diabetes. The severity of their symptoms depends on the nature of the mutation, the function of the affected gene and, in some cases, the influence of additional genetic or environmental factors that modulate severity and penetrance. In some patients, diabetes is accompanied by other syndromic features such as deafness, blindness, microcephaly, liver and intestinal defects, among others. The age of diabetes onset may also vary from neonatal until early adulthood manifestations. Since the different mutations result in diverse clinical presentations, patients usually need different treatments that range from just diet and exercise, to the requirement of exogenous insulin or other hypoglycemic drugs, e.g., sulfonylureas or glucagon-like peptide 1 analogs to control their glycemia. As a consequence, awareness and correct diagnosis are crucial for the proper management and treatment of monogenic diabetes patients. In this chapter, we describe mutations causing different monogenic forms of diabetes associated with inadequate pancreas development or impaired β-cell function and survival, and discuss the molecular mechanisms involved in β-cell demise., Competing Interests: Conflicts of interest All the authors declare to have no conflict of interest., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
30. YIPF5 mutations cause neonatal diabetes and microcephaly through endoplasmic reticulum stress.
- Author
-
De Franco E, Lytrivi M, Ibrahim H, Montaser H, Wakeling MN, Fantuzzi F, Patel K, Demarez C, Cai Y, Igoillo-Esteve M, Cosentino C, Lithovius V, Vihinen H, Jokitalo E, Laver TW, Johnson MB, Sawatani T, Shakeri H, Pachera N, Haliloglu B, Ozbek MN, Unal E, Yıldırım R, Godbole T, Yildiz M, Aydin B, Bilheu A, Suzuki I, Flanagan SE, Vanderhaeghen P, Senée V, Julier C, Marchetti P, Eizirik DL, Ellard S, Saarimäki-Vire J, Otonkoski T, Cnop M, and Hattersley AT
- Subjects
- Cell Line, Female, Human Embryonic Stem Cells metabolism, Human Embryonic Stem Cells pathology, Humans, Induced Pluripotent Stem Cells metabolism, Induced Pluripotent Stem Cells pathology, Infant, Newborn, Insulin-Secreting Cells metabolism, Insulin-Secreting Cells pathology, Male, Neurons metabolism, Neurons pathology, Diabetes Mellitus embryology, Diabetes Mellitus genetics, Diabetes Mellitus pathology, Endoplasmic Reticulum Stress genetics, Genetic Diseases, Inborn embryology, Genetic Diseases, Inborn genetics, Genetic Diseases, Inborn pathology, Infant, Newborn, Diseases embryology, Infant, Newborn, Diseases genetics, Infant, Newborn, Diseases pathology, Microcephaly embryology, Microcephaly genetics, Microcephaly pathology, Mutation, Vesicular Transport Proteins genetics, Vesicular Transport Proteins metabolism
- Abstract
Neonatal diabetes is caused by single gene mutations reducing pancreatic β cell number or impairing β cell function. Understanding the genetic basis of rare diabetes subtypes highlights fundamental biological processes in β cells. We identified 6 patients from 5 families with homozygous mutations in the YIPF5 gene, which is involved in trafficking between the endoplasmic reticulum (ER) and the Golgi. All patients had neonatal/early-onset diabetes, severe microcephaly, and epilepsy. YIPF5 is expressed during human brain development, in adult brain and pancreatic islets. We used 3 human β cell models (YIPF5 silencing in EndoC-βH1 cells, YIPF5 knockout and mutation knockin in embryonic stem cells, and patient-derived induced pluripotent stem cells) to investigate the mechanism through which YIPF5 loss of function affects β cells. Loss of YIPF5 function in stem cell-derived islet cells resulted in proinsulin retention in the ER, marked ER stress, and β cell failure. Partial YIPF5 silencing in EndoC-βH1 cells and a patient mutation in stem cells increased the β cell sensitivity to ER stress-induced apoptosis. We report recessive YIPF5 mutations as the genetic cause of a congenital syndrome of microcephaly, epilepsy, and neonatal/early-onset diabetes, highlighting a critical role of YIPF5 in β cells and neurons. We believe this is the first report of mutations disrupting the ER-to-Golgi trafficking, resulting in diabetes.
- Published
- 2020
- Full Text
- View/download PDF
31. Combined transcriptome and proteome profiling of the pancreatic β-cell response to palmitate unveils key pathways of β-cell lipotoxicity.
- Author
-
Lytrivi M, Ghaddar K, Lopes M, Rosengren V, Piron A, Yi X, Johansson H, Lehtiö J, Igoillo-Esteve M, Cunha DA, Marselli L, Marchetti P, Ortsäter H, Eizirik DL, and Cnop M
- Subjects
- Apoptosis, Humans, Palmitates toxicity, Proteome, Proteomics, Transcriptome, Diabetes Mellitus, Type 2, Insulin-Secreting Cells
- Abstract
Background: Prolonged exposure to elevated free fatty acids induces β-cell failure (lipotoxicity) and contributes to the pathogenesis of type 2 diabetes. In vitro exposure of β-cells to the saturated free fatty acid palmitate is a valuable model of lipotoxicity, reproducing features of β-cell failure observed in type 2 diabetes. In order to map the β-cell response to lipotoxicity, we combined RNA-sequencing of palmitate-treated human islets with iTRAQ proteomics of insulin-secreting INS-1E cells following a time course exposure to palmitate., Results: Crossing transcriptome and proteome of palmitate-treated β-cells revealed 85 upregulated and 122 downregulated genes at both transcript and protein level. Pathway analysis identified lipid metabolism, oxidative stress, amino-acid metabolism and cell cycle pathways among the most enriched palmitate-modified pathways. Palmitate induced gene expression changes compatible with increased free fatty acid mitochondrial import and β-oxidation, decreased lipogenesis and modified cholesterol transport. Palmitate modified genes regulating endoplasmic reticulum (ER) function, ER-to-Golgi transport and ER stress pathways. Furthermore, palmitate modulated cAMP/protein kinase A (PKA) signaling, inhibiting expression of PKA anchoring proteins and downregulating the GLP-1 receptor. SLC7 family amino-acid transporters were upregulated in response to palmitate but this induction did not contribute to β-cell demise. To unravel critical mediators of lipotoxicity upstream of the palmitate-modified genes, we identified overrepresented transcription factor binding sites and performed network inference analysis. These identified LXR, PPARα, FOXO1 and BACH1 as key transcription factors orchestrating the metabolic and oxidative stress responses to palmitate., Conclusions: This is the first study to combine transcriptomic and sensitive time course proteomic profiling of palmitate-exposed β-cells. Our results provide comprehensive insight into gene and protein expression changes, corroborating and expanding beyond previous findings. The identification of critical drivers and pathways of the β-cell lipotoxic response points to novel therapeutic targets for type 2 diabetes.
- Published
- 2020
- Full Text
- View/download PDF
32. Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxia.
- Author
-
Igoillo-Esteve M, Oliveira AF, Cosentino C, Fantuzzi F, Demarez C, Toivonen S, Hu A, Chintawar S, Lopes M, Pachera N, Cai Y, Abdulkarim B, Rai M, Marselli L, Marchetti P, Tariq M, Jonas JC, Boscolo M, Pandolfo M, Eizirik DL, and Cnop M
- Subjects
- Adolescent, Adult, Aged, Animals, Brain pathology, Cerebellum pathology, Disease Models, Animal, Exenatide therapeutic use, Female, Friedreich Ataxia genetics, Friedreich Ataxia metabolism, Ganglia, Spinal pathology, Gene Knock-In Techniques, Glucagon-Like Peptide 1 analogs & derivatives, Glucagon-Like Peptide 1 metabolism, Humans, Insulin metabolism, Insulin-Secreting Cells metabolism, Iron metabolism, Male, Mice, Mice, Knockout, Middle Aged, Oxidative Stress, Reactive Oxygen Species metabolism, Trinucleotide Repeat Expansion, Young Adult, Frataxin, Exenatide pharmacology, Friedreich Ataxia drug therapy, Gene Expression Regulation drug effects, Iron-Binding Proteins genetics, Iron-Binding Proteins metabolism, Mitochondria metabolism
- Abstract
Friedreich ataxia is an autosomal recessive neurodegenerative disease associated with a high diabetes prevalence. No treatment is available to prevent or delay disease progression. Friedreich ataxia is caused by intronic GAA trinucleotide repeat expansions in the frataxin-encoding FXN gene that reduce frataxin expression, impair iron-sulfur cluster biogenesis, cause oxidative stress, and result in mitochondrial dysfunction and apoptosis. Here we examined the metabolic, neuroprotective, and frataxin-inducing effects of glucagon-like peptide-1 (GLP-1) analogs in in vivo and in vitro models and in patients with Friedreich ataxia. The GLP-1 analog exenatide improved glucose homeostasis of frataxin-deficient mice through enhanced insulin content and secretion in pancreatic β cells. Exenatide induced frataxin and iron-sulfur cluster-containing proteins in β cells and brain and was protective to sensory neurons in dorsal root ganglia. GLP-1 analogs also induced frataxin expression, reduced oxidative stress, and improved mitochondrial function in Friedreich ataxia patients' induced pluripotent stem cell-derived β cells and sensory neurons. The frataxin-inducing effect of exenatide was confirmed in a pilot trial in Friedreich ataxia patients, showing modest frataxin induction in platelets over a 5-week treatment course. Taken together, GLP-1 analogs improve mitochondrial function in frataxin-deficient cells and induce frataxin expression. Our findings identify incretin receptors as a therapeutic target in Friedreich ataxia.
- Published
- 2020
- Full Text
- View/download PDF
33. A Review of Mouse Models of Monogenic Diabetes and ER Stress Signaling.
- Author
-
Salpea P, Cosentino C, and Igoillo-Esteve M
- Subjects
- Animals, Diabetes Mellitus, Experimental metabolism, Diabetes Mellitus, Type 2 metabolism, Female, Glucose Intolerance physiopathology, Insulin Secretion, Insulin-Secreting Cells metabolism, Male, Mice, Mice, Mutant Strains, Phenotype, Signal Transduction, Diabetes Mellitus, Experimental genetics, Diabetes Mellitus, Type 2 genetics, Endoplasmic Reticulum metabolism, Endoplasmic Reticulum Stress
- Abstract
Diabetes is a major public health problem: it is estimated that 420 million people are affected globally. Monogenic forms of diabetes are less common, but variants in monogenic diabetes genes have been shown to contribute to type 2 diabetes risk. In vitro and in vivo models of monogenic forms of diabetes related to the endoplasmic reticulum (ER) stress response provided compelling evidence on the role of ER stress and dysregulated ER stress signaling on β cell demise in type 1 and type 2 diabetes. In this chapter, we describe the genetics, background, and phenotype of ER stress-related monogenic diabetes mouse models, and we comment on their advantages and disadvantages. We conclude that these mouse models are very useful tools for monogenic diabetes molecular pathogenesis studies, although there is a variability on the methodology that is used. Regarding the use of these models for therapeutic testing of ER stress modulators, a specific consideration should be given to the fact that they recapitulate some, but not all, the phenotypic characteristics of the human disease.
- Published
- 2020
- Full Text
- View/download PDF
34. The tRNA Epitranscriptome and Diabetes: Emergence of tRNA Hypomodifications as a Cause of Pancreatic β-Cell Failure.
- Author
-
Cosentino C, Cnop M, and Igoillo-Esteve M
- Subjects
- Animals, Diabetes Mellitus metabolism, Humans, Models, Genetic, Mutation, RNA, Transfer metabolism, tRNA Methyltransferases genetics, tRNA Methyltransferases metabolism, Diabetes Mellitus genetics, Insulin-Secreting Cells metabolism, Protein Biosynthesis, RNA Processing, Post-Transcriptional, RNA, Transfer genetics
- Abstract
tRNAs are crucial noncoding RNA molecules that serve as amino acid carriers during protein synthesis. The transcription of tRNA genes is a highly regulated process. The tRNA pool is tissue and cell specific, it varies during development, and it is modulated by the environment. tRNAs are highly posttranscriptionally modified by specific tRNA-modifying enzymes. The tRNA modification signature of a cell determines the tRNA epitranscriptome. Perturbations in the tRNA epitranscriptome, as a consequence of mutations in tRNAs and tRNA-modifying enzymes or environmental exposure, have been associated with human disease, including diabetes. tRNA fragmentation induced by impaired tRNA modifications or dietary factors has been linked to pancreatic β-cell demise and paternal inheritance of metabolic traits. Herein, we review recent findings that associate tRNA epitranscriptome perturbations with diabetes., (Copyright © 2019 Endocrine Society.)
- Published
- 2019
- Full Text
- View/download PDF
35. Inflammatory stress in islet β-cells: therapeutic implications for type 2 diabetes?
- Author
-
Lytrivi M, Igoillo-Esteve M, and Cnop M
- Subjects
- Animals, Anti-Inflammatory Agents therapeutic use, Antioxidants therapeutic use, Blood Glucose drug effects, Blood Glucose metabolism, Diabetes Mellitus, Type 2 metabolism, Diabetes Mellitus, Type 2 pathology, Diffusion of Innovation, Drug Design, Humans, Hypoglycemic Agents adverse effects, Inflammation Mediators metabolism, Insulin-Secreting Cells metabolism, Insulin-Secreting Cells pathology, Molecular Targeted Therapy, Pancreatitis metabolism, Pancreatitis pathology, Diabetes Mellitus, Type 2 drug therapy, Endoplasmic Reticulum Stress drug effects, Hypoglycemic Agents therapeutic use, Inflammation Mediators antagonists & inhibitors, Insulin-Secreting Cells drug effects, Oxidative Stress drug effects, Pancreatitis drug therapy
- Abstract
Type 2 diabetes is a common complex disease. Relatively little is known about the underlying pathophysiology. Mild islet inflammation has been suggested to play a pathogenic role; here we review the available evidence. Mild islet inflammation is histologically detected in pancreas sections of type 2 diabetic patients. In experimental models, it can be triggered by excess nutrients, amyloid, lipopolysaccharide, and endoplasmic reticulum and oxidative stress. Transcriptome studies do not consistently identify pro-inflammatory gene expression signatures in type 2 diabetic islets, and genetic evidence calls into question the causality of inflammation. Several anti-inflammatory medications confer a modest glucose-lowering effect, supporting the role for inflammation in type 2 diabetes. Whether these anti-inflammatory therapies target inflammation in islets or in other metabolically relevant tissues remains unknown., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
36. Pancreatic β-cell tRNA hypomethylation and fragmentation link TRMT10A deficiency with diabetes.
- Author
-
Cosentino C, Toivonen S, Diaz Villamil E, Atta M, Ravanat JL, Demine S, Schiavo AA, Pachera N, Deglasse JP, Jonas JC, Balboa D, Otonkoski T, Pearson ER, Marchetti P, Eizirik DL, Cnop M, and Igoillo-Esteve M
- Subjects
- Aged, Animals, Apoptosis genetics, Cell Death genetics, Cell Differentiation genetics, Cells, Cultured, DNA Fragmentation, Diabetes Mellitus metabolism, Genetic Linkage, Humans, Induced Pluripotent Stem Cells physiology, Insulin-Secreting Cells physiology, Methyltransferases deficiency, Methyltransferases metabolism, Middle Aged, Mutation, Rats, DNA Methylation, Diabetes Mellitus genetics, Insulin-Secreting Cells metabolism, Methyltransferases genetics, RNA, Transfer metabolism
- Abstract
Transfer RNAs (tRNAs) are non-coding RNA molecules essential for protein synthesis. Post-transcriptionally they are heavily modified to improve their function, folding and stability. Intronic polymorphisms in CDKAL1, a tRNA methylthiotransferase, are associated with increased type 2 diabetes risk. Loss-of-function mutations in TRMT10A, a tRNA methyltransferase, are a monogenic cause of early onset diabetes and microcephaly. Here we confirm the role of TRMT10A as a guanosine 9 tRNA methyltransferase, and identify tRNAGln and tRNAiMeth as two of its targets. Using RNA interference and induced pluripotent stem cell-derived pancreatic β-like cells from healthy controls and TRMT10A-deficient patients we demonstrate that TRMT10A deficiency induces oxidative stress and triggers the intrinsic pathway of apoptosis in β-cells. We show that tRNA guanosine 9 hypomethylation leads to tRNAGln fragmentation and that 5'-tRNAGln fragments mediate TRMT10A deficiency-induced β-cell death. This study unmasks tRNA hypomethylation and fragmentation as a hitherto unknown mechanism of pancreatic β-cell demise relevant to monogenic and polygenic forms of diabetes.
- Published
- 2018
- Full Text
- View/download PDF
37. JNK Activation of BIM Promotes Hepatic Oxidative Stress, Steatosis, and Insulin Resistance in Obesity.
- Author
-
Litwak SA, Pang L, Galic S, Igoillo-Esteve M, Stanley WJ, Turatsinze JV, Loh K, Thomas HE, Sharma A, Trepo E, Moreno C, Gough DJ, Eizirik DL, de Haan JB, and Gurzov EN
- Subjects
- Animals, Cells, Cultured, Enzyme Activation, Fatty Acids metabolism, Humans, Mice, Mice, Inbred C57BL, Reactive Oxygen Species metabolism, Bcl-2-Like Protein 11 physiology, Fatty Liver etiology, Insulin Resistance, JNK Mitogen-Activated Protein Kinases physiology, Liver metabolism, Obesity metabolism, Oxidative Stress
- Abstract
The members of the BCL-2 family are crucial regulators of the mitochondrial pathway of apoptosis in normal physiology and disease. Besides their role in cell death, BCL-2 proteins have been implicated in the regulation of mitochondrial oxidative phosphorylation and cellular metabolism. It remains unclear, however, whether these proteins have a physiological role in glucose homeostasis and metabolism in vivo. In this study, we report that fat accumulation in the liver increases c-Jun N-terminal kinase-dependent BCL-2 interacting mediator of cell death (BIM) expression in hepatocytes. To determine the consequences of hepatic BIM deficiency in diet-induced obesity, we generated liver-specific BIM-knockout (BLKO) mice. BLKO mice had lower hepatic lipid content, increased insulin signaling, and improved global glucose metabolism. Consistent with these findings, lipogenic and lipid uptake genes were downregulated and lipid oxidation enhanced in obese BLKO mice. Mechanistically, BIM deficiency improved mitochondrial function and decreased oxidative stress and oxidation of protein tyrosine phosphatases, and ameliorated activation of peroxisome proliferator-activated receptor γ/sterol regulatory element-binding protein 1/CD36 in hepatocytes from high fat-fed mice. Importantly, short-term knockdown of BIM rescued obese mice from insulin resistance, evidenced by reduced fat accumulation and improved insulin sensitivity. Our data indicate that BIM is an important regulator of liver dysfunction in obesity and a novel therapeutic target for restoring hepatocyte function., (© 2017 by the American Diabetes Association.)
- Published
- 2017
- Full Text
- View/download PDF
38. Endoplasmic reticulum stress and eIF2α phosphorylation: The Achilles heel of pancreatic β cells.
- Author
-
Cnop M, Toivonen S, Igoillo-Esteve M, and Salpea P
- Subjects
- Animals, Apoptosis, Cell Death, Diabetes Mellitus metabolism, Endoplasmic Reticulum metabolism, Humans, Phosphorylation, Signal Transduction, Unfolded Protein Response, eIF-2 Kinase metabolism, Endoplasmic Reticulum Stress physiology, Eukaryotic Initiation Factor-2 metabolism, Insulin-Secreting Cells metabolism
- Abstract
Background: Pancreatic β cell dysfunction and death are central in the pathogenesis of most if not all forms of diabetes. Understanding the molecular mechanisms underlying β cell failure is important to develop β cell protective approaches., Scope of Review: Here we review the role of endoplasmic reticulum stress and dysregulated endoplasmic reticulum stress signaling in β cell failure in monogenic and polygenic forms of diabetes. There is substantial evidence for the presence of endoplasmic reticulum stress in β cells in type 1 and type 2 diabetes. Direct evidence for the importance of this stress response is provided by an increasing number of monogenic forms of diabetes. In particular, mutations in the PERK branch of the unfolded protein response provide insight into its importance for human β cell function and survival. The knowledge gained from different rodent models is reviewed. More disease- and patient-relevant models, using human induced pluripotent stem cells differentiated into β cells, will further advance our understanding of pathogenic mechanisms. Finally, we review the therapeutic modulation of endoplasmic reticulum stress and signaling in β cells., Major Conclusions: Pancreatic β cells are sensitive to excessive endoplasmic reticulum stress and dysregulated eIF2α phosphorylation, as indicated by transcriptome data, monogenic forms of diabetes and pharmacological studies. This should be taken into consideration when devising new therapeutic approaches for diabetes.
- Published
- 2017
- Full Text
- View/download PDF
39. Guanabenz Sensitizes Pancreatic β Cells to Lipotoxic Endoplasmic Reticulum Stress and Apoptosis.
- Author
-
Abdulkarim B, Hernangomez M, Igoillo-Esteve M, Cunha DA, Marselli L, Marchetti P, Ladriere L, and Cnop M
- Subjects
- Animals, Cells, Cultured, Drug Resistance drug effects, Humans, Insulin-Secreting Cells metabolism, Male, Rats, Rats, Wistar, Antihypertensive Agents pharmacology, Apoptosis drug effects, Endoplasmic Reticulum Stress drug effects, Guanabenz pharmacology, Insulin-Secreting Cells drug effects, Lipids toxicity
- Abstract
Deficient as well as excessive/prolonged endoplasmic reticulum (ER) stress signaling can lead to pancreatic β cell failure and the development of diabetes. Saturated free fatty acids (FFAs) such as palmitate induce lipotoxic ER stress in pancreatic β cells. One of the main ER stress response pathways is under the control of the protein kinase R-like endoplasmic reticulum kinase (PERK), leading to phosphorylation of the eukaryotic translation initiation factor 2 (eIF2α). The antihypertensive drug guanabenz has been shown to inhibit eIF2α dephosphorylation and protect cells from ER stress. Here we examined whether guanabenz protects pancreatic β cells from lipotoxicity. Guanabenz induced β cell dysfunction in vitro and in vivo in rodents and led to impaired glucose tolerance. The drug significantly potentiated FFA-induced cell death in clonal rat β cells and in rat and human islets. Guanabenz enhanced FFA-induced eIF2α phosphorylation and expression of the downstream proapoptotic gene C/EBP homologous protein (CHOP), which mediated the sensitization to lipotoxicity. Thus, guanabenz does not protect β cells from ER stress; instead, it potentiates lipotoxic ER stress through PERK/eIF2α/CHOP signaling. These data demonstrate the crucial importance of the tight regulation of eIF2α phosphorylation for the normal function and survival of pancreatic β cells., (Copyright © 2017 Endocrine Society.)
- Published
- 2017
- Full Text
- View/download PDF
40. A Missense Mutation in PPP1R15B Causes a Syndrome Including Diabetes, Short Stature, and Microcephaly.
- Author
-
Abdulkarim B, Nicolino M, Igoillo-Esteve M, Daures M, Romero S, Philippi A, Senée V, Lopes M, Cunha DA, Harding HP, Derbois C, Bendelac N, Hattersley AT, Eizirik DL, Ron D, Cnop M, and Julier C
- Subjects
- Adolescent, Adult, Female, Humans, Male, Syndrome, Diabetes Mellitus genetics, Growth Disorders genetics, Microcephaly genetics, Mutation, Missense, Protein Phosphatase 1 genetics
- Abstract
Dysregulated endoplasmic reticulum stress and phosphorylation of eukaryotic translation initiation factor 2α (eIF2α) are associated with pancreatic β-cell failure and diabetes. Here, we report the first homozygous mutation in the PPP1R15B gene (also known as constitutive repressor of eIF2α phosphorylation [CReP]) encoding the regulatory subunit of an eIF2α-specific phosphatase in two siblings affected by a novel syndrome of diabetes of youth with short stature, intellectual disability, and microcephaly. The R658C mutation in PPP1R15B affects a conserved amino acid within the domain important for protein phosphatase 1 (PP1) binding. The R658C mutation decreases PP1 binding and eIF2α dephosphorylation and results in β-cell apoptosis. Our findings support the concept that dysregulated eIF2α phosphorylation, whether decreased by mutation of the kinase (EIF2AK3) in Wolcott-Rallison syndrome or increased by mutation of the phosphatase (PPP1R15B), is deleterious to β-cells and other secretory tissues, resulting in diabetes associated with multisystem abnormalities., (© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.)
- Published
- 2015
- Full Text
- View/download PDF
41. Cytokines induce endoplasmic reticulum stress in human, rat and mouse beta cells via different mechanisms.
- Author
-
Brozzi F, Nardelli TR, Lopes M, Millard I, Barthson J, Igoillo-Esteve M, Grieco FA, Villate O, Oliveira JM, Casimir M, Bugliani M, Engin F, Hotamisligil GS, Marchetti P, and Eizirik DL
- Subjects
- Animals, Cell Line, Cell Survival drug effects, Cytokines pharmacology, Enzyme Inhibitors pharmacology, Humans, Insulin-Secreting Cells metabolism, Male, Mice, Nitric Oxide Synthase Type II antagonists & inhibitors, Rats, Rats, Wistar, Taurochenodeoxycholic Acid pharmacology, Transcription Factor CHOP pharmacology, omega-N-Methylarginine pharmacology, Endoplasmic Reticulum Stress drug effects, Insulin-Secreting Cells drug effects, Interferon-gamma pharmacology, Interleukin-1beta pharmacology, Signal Transduction drug effects, Tumor Necrosis Factor-alpha pharmacology
- Abstract
Aims/hypothesis: Proinflammatory cytokines contribute to beta cell damage in type 1 diabetes in part through activation of endoplasmic reticulum (ER) stress. In rat beta cells, cytokine-induced ER stress involves NO production and consequent inhibition of the ER Ca(2+) transporting ATPase sarco/endoplasmic reticulum Ca(2+) pump 2 (SERCA2B). However, the mechanisms by which cytokines induce ER stress and apoptosis in mouse and human pancreatic beta cells remain unclear. The purpose of this study is to elucidate the role of ER stress on cytokine-induced beta cell apoptosis in these three species and thus solve ongoing controversies in the field., Methods: Rat and mouse insulin-producing cells, human pancreatic islets and human EndoC-βH1 cells were exposed to the cytokines IL-1β, TNF-α and IFN-γ, with or without NO inhibition. A global comparison of cytokine-modulated gene expression in human, mouse and rat beta cells was also performed. The chemical chaperone tauroursodeoxycholic acid (TUDCA) and suppression of C/EBP homologous protein (CHOP) were used to assess the role of ER stress in cytokine-induced apoptosis of human beta cells., Results: NO plays a key role in cytokine-induced ER stress in rat islets, but not in mouse or human islets. Bioinformatics analysis indicated greater similarity between human and mouse than between human and rat global gene expression after cytokine exposure. The chemical chaperone TUDCA and suppression of CHOP or c-Jun N-terminal kinase (JNK) protected human beta cells against cytokine-induced apoptosis., Conclusions/interpretation: These observations clarify previous results that were discrepant owing to the use of islets from different species, and confirm that cytokine-induced ER stress contributes to human beta cell death, at least in part via JNK activation.
- Published
- 2015
- Full Text
- View/download PDF
42. In vitro use of free fatty acids bound to albumin: A comparison of protocols.
- Author
-
Oliveira AF, Cunha DA, Ladriere L, Igoillo-Esteve M, Bugliani M, Marchetti P, and Cnop M
- Subjects
- Albumins metabolism, Animals, Cattle, Fatty Acids, Nonesterified metabolism, Humans, Oleic Acid analysis, Oleic Acid metabolism, Palmitates analysis, Palmitates metabolism, Protein Binding, Albumins analysis, Fatty Acids, Nonesterified analysis
- Published
- 2015
- Full Text
- View/download PDF
43. Unveiling a common mechanism of apoptosis in β-cells and neurons in Friedreich's ataxia.
- Author
-
Igoillo-Esteve M, Gurgul-Convey E, Hu A, Romagueira Bichara Dos Santos L, Abdulkarim B, Chintawar S, Marselli L, Marchetti P, Jonas JC, Eizirik DL, Pandolfo M, and Cnop M
- Subjects
- Animals, Cell Line, Diabetes Mellitus etiology, Diabetes Mellitus genetics, Diabetes Mellitus metabolism, Diabetes Mellitus physiopathology, Female, Friedreich Ataxia complications, Friedreich Ataxia genetics, Friedreich Ataxia metabolism, Humans, Insulin-Secreting Cells metabolism, Iron-Binding Proteins genetics, Iron-Binding Proteins metabolism, Male, Middle Aged, Neurons metabolism, Oxidative Stress, Rats, Rats, Wistar, Frataxin, Apoptosis, Friedreich Ataxia physiopathology, Insulin-Secreting Cells cytology, Neurons cytology
- Abstract
Friedreich's ataxia (FRDA) is a neurodegenerative disorder associated with cardiomyopathy and diabetes. Effective therapies for FRDA are an urgent unmet need; there are currently no options to prevent or treat this orphan disease. FRDA is caused by reduced expression of the mitochondrial protein frataxin. We have previously demonstrated that pancreatic β-cell dysfunction and death cause diabetes in FRDA. This is secondary to mitochondrial dysfunction and apoptosis but the underlying molecular mechanisms are not known. Here we show that β-cell demise in frataxin deficiency is the consequence of oxidative stress-mediated activation of the intrinsic pathway of apoptosis. The pro-apoptotic Bcl-2 family members Bad, DP5 and Bim are the key mediators of frataxin deficiency-induced β-cell death. Importantly, the intrinsic pathway of apoptosis is also activated in FRDA patients' induced pluripotent stem cell-derived neurons. Interestingly, cAMP induction normalizes mitochondrial oxidative status and fully prevents activation of the intrinsic pathway of apoptosis in frataxin-deficient β-cells and neurons. This preclinical study suggests that incretin analogs hold potential to prevent/delay both diabetes and neurodegeneration in FRDA., (© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
- Published
- 2015
- Full Text
- View/download PDF
44. RNA sequencing identifies dysregulation of the human pancreatic islet transcriptome by the saturated fatty acid palmitate.
- Author
-
Cnop M, Abdulkarim B, Bottu G, Cunha DA, Igoillo-Esteve M, Masini M, Turatsinze JV, Griebel T, Villate O, Santin I, Bugliani M, Ladriere L, Marselli L, McCarthy MI, Marchetti P, Sammeth M, and Eizirik DL
- Subjects
- Animals, Apoptosis drug effects, Apoptosis genetics, Blotting, Western, Cell Line, Cells, Cultured, Diabetes Mellitus, Type 2 metabolism, Endoplasmic Reticulum Stress drug effects, Female, Gene Expression Regulation, Enzymologic, Genetic Predisposition to Disease, Humans, Inflammation metabolism, Islets of Langerhans drug effects, Male, Signal Transduction, Transcriptome, Diabetes Mellitus, Type 2 genetics, Endoplasmic Reticulum Stress genetics, Inflammation genetics, Islets of Langerhans metabolism, Palmitates metabolism, Sequence Analysis, RNA
- Abstract
Pancreatic β-cell dysfunction and death are central in the pathogenesis of type 2 diabetes (T2D). Saturated fatty acids cause β-cell failure and contribute to diabetes development in genetically predisposed individuals. Here we used RNA sequencing to map transcripts expressed in five palmitate-treated human islet preparations, observing 1,325 modified genes. Palmitate induced fatty acid metabolism and endoplasmic reticulum (ER) stress. Functional studies identified novel mediators of adaptive ER stress signaling. Palmitate modified genes regulating ubiquitin and proteasome function, autophagy, and apoptosis. Inhibition of autophagic flux and lysosome function contributed to lipotoxicity. Palmitate inhibited transcription factors controlling β-cell phenotype, including PAX4 and GATA6. Fifty-nine T2D candidate genes were expressed in human islets, and 11 were modified by palmitate. Palmitate modified expression of 17 splicing factors and shifted alternative splicing of 3,525 transcripts. Ingenuity Pathway Analysis of modified transcripts and genes confirmed that top changed functions related to cell death. Database for Annotation, Visualization and Integrated Discovery (DAVID) analysis of transcription factor binding sites in palmitate-modified transcripts revealed a role for PAX4, GATA, and the ER stress response regulators XBP1 and ATF6. This human islet transcriptome study identified novel mechanisms of palmitate-induced β-cell dysfunction and death. The data point to cross talk between metabolic stress and candidate genes at the β-cell level., (© 2014 by the American Diabetes Association.)
- Published
- 2014
- Full Text
- View/download PDF
45. tRNA methyltransferase homolog gene TRMT10A mutation in young onset diabetes and primary microcephaly in humans.
- Author
-
Igoillo-Esteve M, Genin A, Lambert N, Désir J, Pirson I, Abdulkarim B, Simonis N, Drielsma A, Marselli L, Marchetti P, Vanderhaeghen P, Eizirik DL, Wuyts W, Julier C, Chakera AJ, Ellard S, Hattersley AT, Abramowicz M, and Cnop M
- Subjects
- Adult, Age of Onset, Animals, Apoptosis genetics, Diabetes Mellitus, Type 2 complications, Female, Genetic Linkage, Humans, Insulin-Secreting Cells metabolism, Insulin-Secreting Cells pathology, Intellectual Disability complications, Intellectual Disability pathology, Male, Microcephaly complications, Microcephaly pathology, Mutation, Pedigree, Rats, Saccharomyces cerevisiae Proteins genetics, tRNA Methyltransferases deficiency, Diabetes Mellitus, Type 2 genetics, Intellectual Disability genetics, Methyltransferases genetics, Microcephaly genetics, tRNA Methyltransferases genetics
- Abstract
We describe a new syndrome of young onset diabetes, short stature and microcephaly with intellectual disability in a large consanguineous family with three affected children. Linkage analysis and whole exome sequencing were used to identify the causal nonsense mutation, which changed an arginine codon into a stop at position 127 of the tRNA methyltransferase homolog gene TRMT10A (also called RG9MTD2). TRMT10A mRNA and protein were absent in lymphoblasts from the affected siblings. TRMT10A is ubiquitously expressed but enriched in brain and pancreatic islets, consistent with the tissues affected in this syndrome. In situ hybridization studies showed that TRMT10A is expressed in human embryonic and fetal brain. TRMT10A is the mammalian ortholog of S. cerevisiae TRM10, previously shown to catalyze the methylation of guanine 9 (m(1)G9) in several tRNAs. Consistent with this putative function, in silico topology prediction indicated that TRMT10A has predominant nuclear localization, which we experimentally confirmed by immunofluorescence and confocal microscopy. TRMT10A localizes to the nucleolus of β- and non-β-cells, where tRNA modifications occur. TRMT10A silencing induces rat and human β-cell apoptosis. Taken together, we propose that TRMT10A deficiency negatively affects β-cell mass and the pool of neurons in the developing brain. This is the first study describing the impact of TRMT10A deficiency in mammals, highlighting a role in the pathogenesis of microcephaly and early onset diabetes. In light of the recent report that the type 2 diabetes candidate gene CDKAL1 is a tRNA methylthiotransferase, the findings in this family suggest broader relevance of tRNA methyltransferases in the pathogenesis of type 2 diabetes., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2013
- Full Text
- View/download PDF
46. Diabetes in Friedreich ataxia.
- Author
-
Cnop M, Mulder H, and Igoillo-Esteve M
- Subjects
- Animals, Cell Survival physiology, Diabetes Mellitus pathology, Disease Models, Animal, Friedreich Ataxia pathology, Humans, Insulin physiology, Insulin-Secreting Cells metabolism, Insulin-Secreting Cells pathology, Iron-Binding Proteins metabolism, Mitochondria metabolism, Neurodegenerative Diseases complications, Pancreas pathology, Risk, Frataxin, Diabetes Mellitus etiology, Friedreich Ataxia complications
- Abstract
Diabetes is a common metabolic disorder in patients with Friedreich ataxia. In this Supplement article, we review the clinical data on diabetes in Friedreich ataxia, and the experimental data from rodent and in vitro models of the disease. Increased body adiposity and insulin resistance are frequently present in Friedreich ataxia, but pancreatic β cell dysfunction and death are a conditio sine qua non for the loss of glucose tolerance and development of diabetes. The loss of frataxin function in mitochondria accounts for these pathogenic processes in Friedreich ataxia. Mitochondria are essential for the sensing of nutrients by the β cell and for the generation of signals that trigger and amplify insulin secretion, known as stimulus-secretion coupling. Moreover, in the intrinsic pathway of apoptosis, pro-apoptotic signals converge on mitochondria, resulting in mitochondrial Bax translocation, membrane permeabilization, cytochrome c release and caspase cleavage. How and at which level frataxin deficiency impacts on these processes in β cells is only partially understood. A better understanding of the molecular mechanisms mediating β cell demise in Friedreich ataxia will pave the way for new therapeutic approaches., (© 2013 International Society for Neurochemistry.)
- Published
- 2013
- Full Text
- View/download PDF
47. The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines.
- Author
-
Eizirik DL, Sammeth M, Bouckenooghe T, Bottu G, Sisino G, Igoillo-Esteve M, Ortis F, Santin I, Colli ML, Barthson J, Bouwens L, Hughes L, Gregory L, Lunter G, Marselli L, Marchetti P, McCarthy MI, and Cnop M
- Subjects
- Adult, Aged, Aged, 80 and over, Alternative Splicing genetics, Animals, Apoptosis, Cell Line, Female, Gene Expression Regulation, Genetic Association Studies, Humans, Immune System, Insulin metabolism, Insulin Secretion, Male, Mice, Middle Aged, Rats, Rats, Wistar, Sequence Analysis, RNA, Transcriptome genetics, Diabetes Mellitus, Type 1 genetics, Diabetes Mellitus, Type 1 immunology, Insulin-Secreting Cells immunology, Insulin-Secreting Cells metabolism, Interferon-gamma genetics, Interferon-gamma metabolism, Interleukin-1beta genetics, Interleukin-1beta metabolism, Islets of Langerhans immunology, Islets of Langerhans metabolism, Signal Transduction
- Abstract
Type 1 diabetes (T1D) is an autoimmune disease in which pancreatic beta cells are killed by infiltrating immune cells and by cytokines released by these cells. Signaling events occurring in the pancreatic beta cells are decisive for their survival or death in diabetes. We have used RNA sequencing (RNA-seq) to identify transcripts, including splice variants, expressed in human islets of Langerhans under control conditions or following exposure to the pro-inflammatory cytokines interleukin-1β (IL-1β) and interferon-γ (IFN-γ). Based on this unique dataset, we examined whether putative candidate genes for T1D, previously identified by GWAS, are expressed in human islets. A total of 29,776 transcripts were identified as expressed in human islets. Expression of around 20% of these transcripts was modified by pro-inflammatory cytokines, including apoptosis- and inflammation-related genes. Chemokines were among the transcripts most modified by cytokines, a finding confirmed at the protein level by ELISA. Interestingly, 35% of the genes expressed in human islets undergo alternative splicing as annotated in RefSeq, and cytokines caused substantial changes in spliced transcripts. Nova1, previously considered a brain-specific regulator of mRNA splicing, is expressed in islets and its knockdown modified splicing. 25/41 of the candidate genes for T1D are expressed in islets, and cytokines modified expression of several of these transcripts. The present study doubles the number of known genes expressed in human islets and shows that cytokines modify alternative splicing in human islet cells. Importantly, it indicates that more than half of the known T1D candidate genes are expressed in human islets. This, and the production of a large number of chemokines and cytokines by cytokine-exposed islets, reinforces the concept of a dialog between pancreatic islets and the immune system in T1D. This dialog is modulated by candidate genes for the disease at both the immune system and beta cell level., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2012
- Full Text
- View/download PDF
48. Ubiquitin fold modifier 1 (UFM1) and its target UFBP1 protect pancreatic beta cells from ER stress-induced apoptosis.
- Author
-
Lemaire K, Moura RF, Granvik M, Igoillo-Esteve M, Hohmeier HE, Hendrickx N, Newgard CB, Waelkens E, Cnop M, and Schuit F
- Subjects
- Amino Acid Sequence, Animals, Endoplasmic Reticulum drug effects, Endoplasmic Reticulum metabolism, Gene Expression Profiling, Gene Expression Regulation drug effects, Gene Knockdown Techniques, Glucose pharmacology, Insulin metabolism, Insulin Secretion, Insulin-Secreting Cells drug effects, Insulin-Secreting Cells metabolism, Male, Mass Spectrometry, Mice, Mice, Inbred C57BL, Molecular Sequence Data, Nerve Tissue Proteins metabolism, Protein Binding drug effects, Protein Transport drug effects, Proteins genetics, RNA, Messenger genetics, RNA, Messenger metabolism, Apoptosis drug effects, Apoptosis genetics, Carrier Proteins metabolism, Cytoprotection drug effects, Endoplasmic Reticulum pathology, Insulin-Secreting Cells cytology, Proteins metabolism, Stress, Physiological drug effects, Stress, Physiological genetics
- Abstract
UFM1 is a member of the ubiquitin like protein family. While the enzymatic cascade of UFM1 conjugation has been elucidated in recent years, the biological function remains largely unknown. In this report we demonstrate that the recently identified C20orf116, which we name UFM1-binding protein 1 containing a PCI domain (UFBP1), and CDK5RAP3 interact with UFM1. Components of the UFM1 conjugation pathway (UFM1, UFBP1, UFL1 and CDK5RAP3) are highly expressed in pancreatic islets of Langerhans and some other secretory tissues. Co-localization of UFM1 with UFBP1 in the endoplasmic reticulum (ER) depends on UFBP1. We demonstrate that ER stress, which is common in secretory cells, induces expression of Ufm1, Ufbp1 and Ufl1 in the beta-cell line INS-1E. siRNA-mediated Ufm1 or Ufbp1 knockdown enhances apoptosis upon ER stress. Silencing the E3 enzyme UFL1, results in similar outcomes, suggesting that UFM1-UFBP1 conjugation is required to prevent ER stress-induced apoptosis. Together, our data suggest that UFM1-UFBP1 participate in preventing ER stress-induced apoptosis in protein secretory cells.
- Published
- 2011
- Full Text
- View/download PDF
49. Glycosomal ABC transporters of Trypanosoma brucei: characterisation of their expression, topology and substrate specificity.
- Author
-
Igoillo-Esteve M, Mazet M, Deumer G, Wallemacq P, and Michels PA
- Subjects
- ATP-Binding Cassette Transporters genetics, Cytosol metabolism, Fatty Acids metabolism, Gene Expression Regulation, Developmental, Protozoan Proteins genetics, Protozoan Proteins metabolism, Substrate Specificity, Trypanosoma brucei brucei genetics, Trypanosoma brucei brucei ultrastructure, ATP-Binding Cassette Transporters metabolism, Acyl Coenzyme A metabolism, Microbodies metabolism, Trypanosoma brucei brucei metabolism
- Abstract
Metabolism in trypanosomatids is compartmentalised with major pathways, notably glycolysis, present in peroxisome-like organelles called glycosomes. To date, little information is available about the transport of metabolites through the glycosomal membrane. Previously, three ATP-binding cassette (ABC) transporters, called GAT1-3 for Glycosomal ABC Transporters 1 to 3, have been identified in the glycosomal membrane of Trypanosoma brucei. Here we report that GAT1 and GAT3 are expressed both in bloodstream and procyclic form trypanosomes, whereas GAT2 is mainly or exclusively expressed in bloodstream-form cells. Protease protection experiments showed that the nucleotide-binding domain of GAT1 and GAT3 is exposed to the cytosol, indicating that these transporters mediate the ATP-dependent uptake of solutes from the cytosol into the glycosomal lumen. Depletion of GAT1 and GAT3 by RNA interference in procyclic cells grown in glucose-containing medium did not affect growth. Surprisingly, GAT1 depletion enhanced the expression of the very different GAT3 protein. Expression knockdown of GAT1, but not GAT3, in procyclic cells cultured in glucose-free medium was lethal. Depletion of GAT1 in glucose-grown procyclic cells caused a modification of the total cellular fatty-acid composition. No or only minor changes were observed in the levels of most fatty acids, including oleate (C18:1), nevertheless the linoleate (C18:2) abundance was significantly increased upon GAT1 silencing. Furthermore, glycosomes purified from procyclic wild-type cells incorporate oleoyl-CoA in a concentration- and ATP-dependent manner, whilst this incorporation was severely reduced in glycosomes from cells in which GAT1 levels had been decreased. Together, these results strongly suggest that GAT1 serves to transport primarily oleoyl-CoA, but possibly also other fatty acids, from the cytosol into the glycosomal lumen and that its depletion results in a cellular linoleate accumulation, probably due to the presence of an active oleate desaturase. The role of intraglycosomal oleoyl-CoA and its essentiality when the trypanosomes are grown in the absence of glucose, are discussed., (Copyright © 2010 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
50. The transcription factor B-cell lymphoma (BCL)-6 modulates pancreatic {beta}-cell inflammatory responses.
- Author
-
Igoillo-Esteve M, Gurzov EN, Eizirik DL, and Cnop M
- Subjects
- Animals, Apoptosis drug effects, Blotting, Western, Cell Line, Cell Survival drug effects, Cell Survival genetics, Colforsin pharmacology, Cytokines pharmacology, Exenatide, Fluorescent Antibody Technique, Insulin-Secreting Cells cytology, Insulin-Secreting Cells drug effects, Male, NF-kappa B genetics, Nitric Oxide Synthase Type II genetics, Peptides pharmacology, Polymerase Chain Reaction, Prolactin pharmacology, Proto-Oncogene Proteins c-bcl-6 genetics, Rats, Rats, Wistar, Venoms pharmacology, fas Receptor genetics, Insulin-Secreting Cells immunology, Insulin-Secreting Cells metabolism, Proto-Oncogene Proteins c-bcl-6 metabolism
- Abstract
Type 1 diabetes is a chronic autoimmune disease with a strong inflammatory component. We have previously shown that expression of the transcriptional repressor B-cell lymphoma (BCL)-6 is very low in pancreatic β-cells, which may favor prolonged proinflammatory responses after exposure to the cytokines IL-1β and interferon γ. Here we investigated whether cytokine-induced inflammation and apoptosis can be prevented in β-cells by BCL-6 expression using plasmid, prolactin, and adenoviral approaches. The induction of mild or abundant BCL-6 expression in β-cells by prolactin or an adenoviral BCL-6 expression construct, respectively, reduced cytokine-induced inflammatory responses in a dose-dependent manner through inhibition of nuclear factor-κB activation. BCL-6 decreased Fas and inducible nitric oxide synthase expression and nitric oxide production, but it inhibited the expression of the antiapoptotic proteins Bcl-2 and JunB while increasing the expression of the proapoptotic death protein 5. The net result of these opposite effects was an augmentation of β-cell apoptosis. In conclusion, BCL-6 expression tones down the unrestrained cytokine-induced proinflammatory response of β-cells but it also favors gene networks leading to apoptosis. This suggests that cytokine-induced proinflammatory and proapoptotic signals can be dissociated in β-cells. Further understanding of these pathways may open new possibilities to improve β-cell survival in early type 1 diabetes or after transplantation.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.